Health insurance company Clover Health (NASDAQ: CLOV) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 50.1% year on year to $496.7 million. Its GAAP loss of $0.05 per share was $0.02 below analysts’ consensus estimates.

Is now the time to buy CLOV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Clover Health’s third quarter was marked by robust revenue growth, yet a negative market reaction reflected investor concerns around profitability and cost trends. Management attributed the strong top-line performance to accelerated membership gains, especially as competitors retrenched. However, CEO Andrew Toy acknowledged that the company "missed our targets on both overall adjusted EBITDA and stars," citing higher-than-expected utilization and challenges managing a surge of new members, which diluted near-term margins and pressured overall results.

Looking ahead, Clover Health’s outlook centers on maturing new member cohorts and expanding the reach of its Clover Assistant technology. Management expects that as recent members transition into returning cohorts, contribution profits will improve, particularly as more users engage with Clover Assistant. CFO Peter Kuipers emphasized that "a 4-star payment year for our PPO plans creates meaningful financial tailwinds" and highlighted the role of ongoing cost discipline and technology enhancements in supporting future profitability.

Key Insights from Management’s Remarks

Management attributed the quarter’s mixed results to rapid membership growth, utilization headwinds, and the evolving impact of Clover Assistant on cohort profitability.

• New member dynamics: The influx of first-year members, driven by competitors’ market exits and changes in benefit design, contributed to revenue growth but weighed on profitability, as new members typically incur higher costs and are slower to benefit from care management tools.
• Utilization pressures: Higher-than-anticipated medical and supplemental benefit utilization, particularly among new members, led to margin compression. Management pointed to increased inpatient, outpatient, and pharmacy expenses as key cost drivers for the period.
• Clover Assistant effectiveness: Returning members managed with Clover Assistant continued to show improved clinical outcomes and contribution profits. The technology enabled Clover Health to achieve top PPO HEDIS quality scores, reinforcing its role as the core driver of sustainable profitability.
• Star ratings shortfall: The company received a 3.5-star rating for the 2026 plan year, falling short of its 4-star goal. Management cited weaknesses in pharmacy-related measures as a primary factor and outlined targeted initiatives to address these gaps.
• Expansion of Counterpart Health: Clover’s technology subsidiary, Counterpart Health, rolled out new AI-powered features and expanded its go-to-market team, aiming to serve both internal plans and third-party payers seeking to manage independent provider networks more effectively.

Drivers of Future Performance

Clover Health’s guidance is driven by the expected maturation of new member cohorts, technology adoption, and evolving industry reimbursement dynamics.

• Cohort maturation and retention: Management projects that as the large influx of new members transitions into returning cohorts, contribution profits will recover due to improved medical cost ratios and stronger engagement with Clover Assistant. High retention rates above 90% are expected to support this transition.
• Technology and quality initiatives: The company is investing in expanding Clover Assistant’s reach and capabilities, particularly among primary care providers. Enhanced AI-driven features and efforts to improve pharmacy management are anticipated to drive better clinical outcomes and support star rating improvement efforts.
• Industry headwinds and tailwinds: While utilization and cost pressures remain a risk, management expects to benefit from favorable CMS (Centers for Medicare & Medicaid Services) rate updates, increased Part D subsidies, and a higher star rating payment year, which together should support margin expansion and profitability in 2026 and beyond.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will watch (1) the rate at which new members transition to profitable returning cohorts under Clover Assistant management, (2) progress in improving pharmacy and supplemental benefit cost controls, and (3) the impact of technology upgrades and Counterpart Health partnerships on provider adoption. Execution on star rating improvement initiatives and maintaining high retention will also be critical markers of success.

Clover Health currently trades at $2.81, down from $3.52 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.